Generated Narrative: Citation 179630

url: Citation 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

identifier: FEvIR Object Identifier/179630, https://pubmed.ncbi.nlm.nih.gov/26092557, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.30

version: 2.0.0-ballot

title: 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

status: Active

date: 2024-11-21 14:09:14+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2016-04-14

lastReviewDate: 2024-02-10

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2015-02-20

statusDate

activity: PubMed Pubstatus of Revised

period: ?? --> 2015-05-08

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2015-05-11

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2015-06-21 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2015-06-21 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2016-04-15 06:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/26092557, https://doi.org/10.1016/j.urolonc.2015.05.012, pii/S1078-1439(15)00235-5

Titles

-	Type	Language	Text
*	Primary title	English	Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

Abstracts

-	Text	Copyright
*	BACKGROUND AND OBJECTIVE: Sequential tissue biopsies taken during clinical trials of novel systemic anticancer therapies for advanced prostate cancer (PCa) may aid pharmacodynamic evaluation and biomarker discovery. We conducted a single institution phase-II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non-castration-resistant PCa with sequential prostatic biopsies. PATIENTS AND METHODS: We randomized 30 patients with newly diagnosed high-grade locally advanced or metastatic (cT3-4/N0-1/M0-1) PCa to receive ADT with (n = 15) or without (n = 15) docetaxel. Transrectal ultrasound-guided prostatic biopsies were taken at randomization and ~22 weeks after treatment initiation. Primary end point: biochemical response rate. Secondary end points: time to progression and tumor profiling. RESULTS: Both treatments appear to be well tolerated, and there was no difference in mean nadir prostate-specific antigen and time to prostate-specific antigen relapse between treatment arms (P>0.05). No adverse effects of pre- and post-treatment prostatic biopsies were observed. The study was neither designed nor sufficiently powered to demonstrate statistically significant differences in oncological outcomes or safety profiles between the 2 treatment arms. CONCLUSIONS: Despite the lack of statistical power, our study suggests that docetaxel and ADT in combination may be well tolerated with apparently similar short-term efficacy compared with ADT alone for high-grade locally advanced or metastatic non-castration-resistant PCa, Sequential prostatic biopsies may provide tissue for tumor profiling to yield mechanistic or prognostic insights relating to novel systemic anticancer therapies.	Copyright © 2015 Elsevier Inc. All rights reserved.

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1873-2496, ISOAbbreviation/Urol Oncol, ISSN Linking/1078-1439, Medline Title Abbreviation/Urol Oncol, NLM Unique ID/9805460

title: Urologic oncology

publisherLocation: United States

citedMedium: Internet

volume: 33

issue: 8

articleDate: 2015-08

publicationDateText: 2015-Aug

language: English

pageString: 337.e1-6

publicationForm

citedMedium: Internet without issue

articleDate: 2015-06-16

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/26092557/

webLocation

classifier: DOI Based

url: https://doi.org/10.1016/j.urolonc.2015.05.012

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Keyword

artifactAssessment: Keywords provided by NOTNLM

classification

type: Chemical

classifier: Androgen Antagonists, Taxoids, Docetaxel

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Rajan P

forenameInitials: P

affiliation: Institute of Cancer Sciences, University of Glasgow, UK. Electronic address: p.rajan@beatson.gla.ac.uk.

entry

contributor: Frew JA

forenameInitials: JA

affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: Wilson JM

forenameInitials: JM

affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: Azzabi AS

forenameInitials: AS

affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: McMenemin RM

forenameInitials: RM

affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: Stockley J

forenameInitials: J

affiliation: Institute of Cancer Sciences, University of Glasgow, UK.

entry

contributor: Soomro NA

forenameInitials: NA

affiliation: Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: Durkan G

forenameInitials: G

affiliation: Newcastle Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: Pedley ID

forenameInitials: ID

affiliation: Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.

entry

contributor: Leung HY

forenameInitials: HY

affiliation: Institute of Cancer Sciences, University of Glasgow, UK; Cancer Research UK Beatson Institute, Bearsden, UK. Electronic address: h.leung@beatson.gla.ac.uk.

Generated Narrative: ArtifactAssessment #keywords0

artifact: Citation 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

content

classifier: Androgen deprivation therapy

content

classifier: Docetaxel

content

classifier: Prostate cancer

content

classifier: Prostatic biopsy

Generated Narrative: Practitioner #contributor0

name: Prabhakar Rajan

Generated Narrative: Practitioner #contributor1

name: John A Frew

Generated Narrative: Practitioner #contributor2

name: James M Wilson

Generated Narrative: Practitioner #contributor3

name: Ashraf S T Azzabi

Generated Narrative: Practitioner #contributor4

name: Rhona M McMenemin

Generated Narrative: Practitioner #contributor5

name: Jacqueline Stockley

Generated Narrative: Practitioner #contributor6

name: Naeem A Soomro

Generated Narrative: Practitioner #contributor7

name: Garrett Durkan

Generated Narrative: Practitioner #contributor8

name: Ian D Pedley

Generated Narrative: Practitioner #contributor9

name: Hing Y Leung

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Androgen Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Biopsy

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Docetaxel

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Feasibility Studies

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Prostatic Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

component

type: qualifier

classifier: surgery

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Taxoids

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes